The safety profile of adjunctive Zonegran (zonisamide), from Eisai, in paediatric patients with partial Epilepsy is confirmed by pooled data...
Preliminary results from a new Phase III study of Zonegran (zonisamide) from Eisai, shows that it is more effective than...
Areas covered: Herein, the authors discuss the pharmacology, clinical efficacy and the adverse effects of zonisamide. The article is derived from clinical trial data, long-term studies, meta-analyses, review articles, text books...
Zonisamide is indicated as: • monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy (see section 5.1); • adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.